Xuedong Liu

Fondatore presso OnKure, Inc.

Health Technology

Relazioni attive

Nome	Sesso	Età	Società collegate	Collaborazione
Anthony D. Piscopio	M	-	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	13 anni
Donna Peak	M	-	Vesicle Therapeutics, Inc. Vesicle Therapeutics, Inc. BiotechnologyHealth Technology Vesicle Therapeutics, Inc. is a biotechnology company that operates in the field of life sciences. The company is based in Niwot, CO. The CEO of the company is Donna Peak.	-
R. Carruthers	M	66	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	5 anni
Nicholas A. Saccomano	M	65	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	-
Isaac Manke	M	47	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	3 anni
Andrew Phillips	M	53	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	3 anni
John DeMattei	M	-	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	-
Guobao Zhao	M	-	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	7 anni